SCHEMBL513221

SCHEMBL513221

CCC(CC)(c1noc(-c2cccnc2)n1)P(=O)(O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.49
CHRNA5 P30532 1/20 0.49
CHRNA4 P43681 1/20 0.49
SMN1; SMN2 Q16637 10/20 0.47
TP53 P04637 8/20 0.47
NPC1 O15118 10/20 0.45
RAB9A P51151 9/20 0.45
MAPT P10636 7/20 0.45
LMNA P02545 1/20 0.45
KMT2A Q03164 1/20 0.45
NFKB1 P19838 2/20 0.44
NFKB2 Q00653 2/20 0.44
RELA Q04206 2/20 0.44
S1PR1 P21453 2/20 0.43
ALDH1A1 P00352 2/20 0.43
NPSR1 Q6W5P4 1/20 0.43
PKM P14618 2/20 0.42
TSHR P16473 1/20 0.42
HTT P42858 1/20 0.42
HSD17B10 Q99714 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL513204 0.86 HDAC6 (0.44) SMN1; SMN2TP53NPC1RAB9AMAPT
SCHEMBL513425 0.85 NPC1 (0.45) SMN1; SMN2TP53NPC1RAB9AMAPT
SCHEMBL513092 0.81 NPC1 (0.46) SMN1; SMN2TP53NPC1RAB9AMAPT
SCHEMBL513589 0.80 NPC1 (0.47) SMN1; SMN2TP53NPC1RAB9AMAPT
SCHEMBL513254 0.80 TP53 (0.45) SMN1; SMN2TP53NPC1RAB9AALDH1A1
SCHEMBL513366 0.78 RAB9A (0.52) SMN1; SMN2TP53NPC1RAB9AMAPT
SCHEMBL512771 0.78 RAB9A (0.49) SMN1; SMN2NPC1RAB9AMAPTLMNA
SCHEMBL512821 0.77 CA2 (0.41) NPC1RAB9AMAPTKMT2AALDH1A1
SCHEMBL513467 0.77 HSD17B10 (0.42) SMN1; SMN2TP53NPC1RAB9AMAPT
SCHEMBL512093 0.75 NPC1 (0.41) SMN1; SMN2TP53NPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS RECORDATI IRELAND LIMITED (IE) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS OPRM1, GRM5, OPRD1 CHRNB2 83/4885CHRNA5 5/4885CHRNA4 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.